AnthracyclinesNaphthacenesAntibiotics, AntineoplasticDaunorubicinDoxorubicinAclarubicinCarubicinIdarubicinEpirubicinBreast NeoplasmsRazoxaneNogalamycinAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsTaxoidsBridged CompoundsLeukemia P388Heart DiseasesDNA Topoisomerases, Type IIAconitic AcidVinblastineDrug Resistance, MultipleP-GlycoproteinDrug Resistance, NeoplasmAnthraquinonesDexrazoxaneChemotherapy, AdjuvantPaclitaxelMitoxantroneReceptor, erbB-2CardiotoxinsDrug Administration ScheduleFluorouracilTreatment OutcomeDrug ResistanceCyclophosphamideLeukemia L1210Antineoplastic Agents, PhytogenicTopoisomerase II InhibitorsDisease-Free SurvivalDeoxycytidineNeoplasmsPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasm MetastasisVerapamilDose-Response Relationship, DrugStreptomycesSalvage TherapyCytarabineLiposomesEtoposideIntercalating AgentsAlopeciaCardiomyopathiesVincristineHeartTumor Cells, CulturedLeukotriene C4SurvivorsDrug Screening Assays, AntitumorDrug InteractionsTrifluoperazinePhthalic AcidsInfusions, IntravenousAntigens, NeoplasmEpothilonesCell SurvivalMitomycinAntibodies, Monoclonal, HumanizedLeukemia, Myeloid, AcuteRemission InductionMultidrug Resistance-Associated ProteinsCalreticulinSurvival AnalysisTime FactorsMethotrexateCell Line, TumorGlycosidesPregnancy Complications, NeoplasticStructure-Activity RelationshipLactoperoxidaseCardiotonic AgentsLeukemia, Promyelocytic, AcuteApoptosis